Myomo (MYO) Stock Forecast & Price Target

Myomo is supported by improving operating momentum, with Q2 unit sales of 211 versus 172 in Q1, while the reimbursement pipeline of 1,491 and insurance-authorized backlog of 218 still indicate meaningful demand visibility. The 2026 revenue guide was raised to $45 million to $47 million from $43 million to $46 million, reflecting confidence in continued U.S. commercialization, ramping Medicare coverage, and expanding European and international sales that were up 32% year-over-year in Q2. The March 2024 CMS ruling materially broadens the addressable market by reimbursing Medicare Part B beneficiaries and O&P providers, and U.S. O&P revenue of $2.9 million in 2025, up 100% year-over-year, underscores an accelerating growth channel.

Myomo is exposed to multiple fundamental weaknesses that pressure its long-term outlook, including balance sheet and liquidity risk, commercialization challenges, and dependence on favorable reimbursement outcomes. As a wearable medical robotics company selling the MyoPro through insurance billing, orthotics and prosthetics providers, and the VA, it faces execution risk in scaling adoption while also needing to maintain regulatory approvals and prove continued safety and efficacy. Competitive pressure, macroeconomic uncertainty, and shifting investor sentiment toward biotech and medtech further heighten the risk that demand, funding access, and operating performance remain volatile.